• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Psyadon announces positive results from ecopipam Tourette’s study

Psyadon announces positive results from ecopipam Tourette’s study

January 19, 2017
CenterWatch Staff

Psyadon Pharmaceuticals, a company focused on treatments for neurological and psychiatric disorders, has announced that its lead product—ecopipam—produced significant reductions in total tic severity scores in children (7-17 years) with Tourette’s Syndrome.

The study’s primary endpoint was a statistically significant reduction in the mean Yale Global Tic Severity Score Total Tic Score (YGTSS-TTS). This is a well-validated and standard measure of the clinical efficacy of drugs treating Tourette’s Syndrome. Ecopipam caused significant reductions in the YGTSS-TTS at both two- and four weeks after initiating treatment. Furthermore, the side effects seen in the subjects taking ecopipam were comparable to those seen in the placebo-treated subjects, including no clinically significant changes in standard clinical lab tests or ECG’s, and no increases in body weights.

“Ecopipam works by blocking the dopamine D1 receptor which differentiates it from any other drug either on the market or currently in development. Since there hasn’t been a mechanistically new drug for the treatment of Tourette’s in over 30 years, this could offer a better option for people who suffer with the disease,” said Richard Chipkin, Ph.D., president and chief executive officer of Psyadon.

Donald Gilbert, M.D., the study’s Principal Investigator and professor and director of the Movement Disorder and Tourette Syndrome clinics at Cincinnati Children's Hospital Medical Center said, “Too many individuals with Tourette’s Syndrome remain symptomatic despite treatment with available drugs, or experience side effects like weight gain or sedation that limit their use. These results demonstrate the efficacy of D1 antagonism, an entirely new approach that doctors and scientists have speculated about for years. As importantly, the subjects in the study tolerated ecopipam very well, with no weight gain, sedation, or heart problems.”

The phase IIb study called “Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years (PSY302),” was a double-blind, randomized, placebo-controlled crossover study conducted to assess the efficacy and safety of ecopipam in children with Tourette’s Syndrome.

Patients were instructed to take the study medication (either ecopipam or placebo) each evening before bedtime over a four-week treatment period. Patients were evaluated in the clinic every other week with telephone contacts on the alternate weeks. The primary efficacy endpoint was the change in the Yale Global Tic Severity Score-Total Tic Score (YGTSS-TTS), a well-validated rating scale typically used in Tourette’s Syndrome trials. The study was fully enrolled at 40 subjects.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing